Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.G. McHutchinson, S.C. Gordon, E.R. Schiff, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[2.]
M.P. Manns, J.G. McHutchinson, S.C. Gordon, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[3.]
National Institutes of Health Consensus Development Conference Panel Statement:.
Management of Hepatitis C.
Hepatology, 26 (1997), pp. 2-10
[4.]
W. Vogel.
Treatment of acute hepatitis C virus infection.
J Hepatol, 31 (1999), pp. 189-192
[5.]
E. Jaeckel, M. Cornberg, H. Wedemeyer, T. Sanantonio, J. Mayer, G. Zar Pastore, et al.
Treatment of acute hepatitis C with interferon alpha-2b.
N Engl J Med, 345 (2001), pp. 1452-1457
[6.]
S. Mukherjee, R.K. Gilroy, D.F. Schafer.
Severe cholestasis in a patient with acute hepatitis C treated with interferon alpha-2b.
Am J Gastroenterol, 97 (2002), pp. 2152-2153
[7.]
M. Oketani, T. Higashi, N. Yamasaki, K. Shinmyozu, M. Osame, T. Arima.
Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick.
J Clin Gastroenterol, 28 (1999), pp. 49-51
[8.]
P. Fabris, G. Tositti, M.T. Giordani, D. Infantolino.
Three times weekly versus daily dose alpha-interferon treatment in acute hepatitis C.
Am J Gastroenterol, 97 (2002), pp. 492-493
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
